Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer

Original title: Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.

Purpose We aimed to investigate the prognostic and predictive value of tumor-infiltrating lymphocytes (TIL) for adjuvant immunotherapy in high-risk early triple-negative breast cancer (TNBC).

By Dieci, Gasparini, Nicolé +26Clinical cancer research : an official journal of the American Association for Cancer ResearchOct 1, 2026

Score█████░░░░░5.4

Key numbers

92% vs
70.4% vs

VerdictA leading story on any desk.

Read the original

Abstract

Purpose We aimed to investigate the prognostic and predictive value of tumor-infiltrating lymphocytes (TIL) for adjuvant immunotherapy in high-risk early triple-negative breast cancer (TNBC). Patients and methods The phase III A-BRAVE trial randomized 466 patients with high-risk early TNBC to adjuvant avelumab or observation after standard therapy. Inclusion criteria allowed 2 strata: stratum A (primary surgery followed by adjuvant chemotherapy, defined at high risk based on pathologic stage) and stratum B (neoadjuvant chemotherapy followed by surgery without pathologic complete response). TILs were centrally assessed on treatment-naïve tumor samples [baseline TILs (BSL-TIL)] and on residual disease (RD) after neoadjuvant chemotherapy (RD-TILs, stratum B). Residual cancer burden (RCB) was assessed in stratum B. Survival endpoints were disease-free survival (DFS), distant DFS (DDFS), and overall survival (OS). Results BSL-TILs were available for 387 patients and RD-TILs for 330 patients (290 with both BSL-TILs and RD-TILs). Higher BSL-TILs were independently associated with improved outcomes across all endpoints. In stratum B, higher RD-TILs showed a significant independent association with improved outcomes, outperforming BSL-TILs. RCB was also independently prognostic. Avelumab improved outcomes only for patients with BSL-TILs ≥30%, particularly in stratum B (3-year DDFS rates, 92% vs. 58.7%; HR, 0.20 in high BSL-TILs and 70.4% vs. 70.1%, HR, 0.92 in low BSL-TILs; interaction P = 0.019). Similar results were obtained for DFS and OS. RCB was not predictive for avelumab benefit. Conclusions TILs may predict benefit from adjuvant immunotherapy in early TNBC. These findings warrant validation and support TIL-guided immunotherapy strategies in future trials.

Maria Vittoria Dieci, Elisa Gasparini, Lorenzo Nicolé, Peter Schmid, Alberto Zambelli, Adolfo Favaretto, Federico Piacentini, Giulia Valeria Bianchi, Marta Mion, Antonella Ferro, Grazia Arpino, Alessandra Emiliani, Saverio Cinieri, Claudio Zamagni, Alessandra Gennari, Simon Spazzapan, Donata Sartori, Fable Zustovich, Stefano Tamberi, Lucia Del Mastro, Michelino de Laurentiis, Antonino Musolino, Katia Cagossi, Daniele Generali, Tommaso Giarratano, Filippo Giovanardi, Gian Luca De Salvo, Pierfranco Conte, Valentina Guarneri

The editor's rubric

Heuristic review

Dimension	Level	Weight	What that level means
Leverage	██░░░ 2	10%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	████░ 4	20%	A qualitative jump: a capability or regime that did not exist before.
Evidence	█████ 5	32%	Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
Novelty	██░░░ 2	8%	A new combination of known ideas.
Trajectory	██░░░ 2	5%	Some room to improve with obvious engineering.
Stakes	███░░ 3	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (relative gain, versus baseline, outperforms); design (randomized, phase 3); verification (p-value, independent replication); stakes (mortality, major disease, prevention or cure).

How the score was computed

rank-2026-09-29

Score█████░░░░░5.4

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Merit: 7.2 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 5.6 / 10; Shrunk toward the desk prior by editor confidence (50%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 92%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Oct 2, 2026, 06:17 UTC)
Field-weighted citation impact0 (reference 3, via openalex, Oct 2, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v2 on Oct 2, 2026, 06:17 UTC. Paper type: clinical.
Categories: Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Lymphocytes, Tumor-Infiltrating, Humans, Neoplasm Staging, Prognosis, Treatment Outcome, Chemotherapy, Adjuvant, Neoadjuvant Therapy
LEAD, No.1 in the Front page edition of October 2, 2026.
TOP, No.2 in the Medicine edition of October 2, 2026.